How has Xeris Biopharma Holdings, Inc.'s exercise of stock options changed year-over-year?

Xeris Biopharma Holdings, Inc.'s exercise of stock options decreased by 100.0% year-over-year, from $99K to $0.

Xeris Biopharma Holdings, Inc. XERS Exercise of stock options

Revenue$83.1M+38.3%

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Operating cash flow$9.9M+198%

CapEx$131.0K—

Free cash flow-$29.1M—

Market cap$1.28B+76.9%

Enterprise value$1.42B+52.7%

P/E106.4×—

P/S4.1×+0.8×

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Return on equity-209.8%—

Debt / equity19.9×—

Current ratio2.1×+0.4×

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept xers:StockOptionsExercisedDuringPeriodButNotYetSettled.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Xeris Biopharma Holdings, Inc.'s exercise of stock options?: Xeris Biopharma Holdings, Inc. (XERS) reported exercise of stock options of $0 in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s exercise of stock options changed year-over-year?: Xeris Biopharma Holdings, Inc.'s exercise of stock options decreased by 100.0% year-over-year, from $99K to $0.